Gamma-glutamyl transpeptidase level associated with metabolic syndrome and proinflammatory parameters in the young Roma population in Eastern Slovakia: A population based study

Central European Journal of Public Health

Volumn 22, Issue , 2014, Pages S43-S50

  Jarčuška, Peter ^a   Janičko, Martin ^a   Dražilová, Sylvia ^b   Senajová, Gabriela ^a   Veselíny, Eduard ^a   Fedacko J ^a   Siegfried, Leonard ^a   Kristian, Pavol ^a   Tkáč, Michal ^c   Pella, Daniel ^a   Mareková, Mária ^d   Gecková, Andrea Madarasová ^d,e   Jarčuška, Pavol ^a   Pastvová, Lýdia ^f   Kollárová, Jana ^f   Kolarèik, Peter ^f   Bobáková, Daniela ^f   Veselská, Zuzana ^f   Babinská, Ingrid ^f   Rosenberger, Jaroslav ^f   Schréter, Ivan ^f   Virág, Ladislav ^f   Birková, Anna ^f   Marta, Kme’Ová ^f   Halánová, Monika ^f   Petrášová, Darina ^f   Cáriková, Katarína ^f   Lovayová, Viera ^f   Merkovská, Lucia ^f   Jedlièková, Lucia ^f   Valková, Ivana ^f   more..

^a Med Faculty of Safarik University   (Slovakia)

^b Department of Internal Medicine Poprad Hospital   (Slovakia)

^c UNIVERSITY OF ECONOMICS IN BRATISLAVA   (Slovakia)

^d P J AFÁRIK UNIVERSITY   (Slovakia)

^e PALACKÝ UNIVERSITY   (Czech Republic)

^f NONE

Author keywords

Ferritin; Gamma glutamyl transpeptidase; Hs CRP; Metabolic syndrome; Non alcoholic fatty liver disease

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; LIPID;

ADOLESCENT; ADULT; ARTICLE; BLOOD; COMORBIDITY; CROSS-SECTIONAL STUDY; DIET; ENZYMOLOGY; ETHNOLOGY; FATTY LIVER; FEMALE; HEALTH SURVEY; HUMAN; INFLAMMATION; MALE; METABOLIC SYNDROME X; METHODOLOGY; MIDDLE AGED; MOTOR ACTIVITY; NONALCOHOLIC FATTY LIVER; PHYSIOLOGY; QUESTIONNAIRE; RISK FACTOR; ROMANI (PEOPLE); RURAL POPULATION; SLOVAKIA; SOCIOECONOMICS; STATISTICS; YOUNG ADULT;

ADOLESCENT; ADULT; C-REACTIVE PROTEIN; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIET; FATTY LIVER; FEMALE; FERRITINS; GAMMA-GLUTAMYLTRANSFERASE; GYPSIES; HEALTH SURVEYS; HUMANS; INFLAMMATION; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; QUESTIONNAIRES; RISK FACTORS; RURAL POPULATION; SLOVAKIA; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84905121246     PISSN: 12107778     EISSN: None     Source Type: Journal    
DOI: 10.21101/cejph.a3901     Document Type: Article

References (50)

1. Irie M, Sohda T, Iwata K, Kunimoto H, Fukunaga A, Kuno S, et al. Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease. J Int Med Res. 2012;40(3):924-33.
2. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001 Aug;38(4):263-355.
3. Banderas DZ, Escobedo J, Gonzalez E, Liceaga MG, Ramírez JC, Castro MG. γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol. 2012 Jul;24(7):805-10.
4. Tahan V, Canbakan B, Balci H, Dane F, Akin H, Can G, et al. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology. 2008 Jul-Aug;55(85):1433-8.
5. Franzini M, Fornaciari I, Fierabracci V, Elawadi HA, Bolognesi V, Maltinti S, et al. Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int. 2012 Apr;32(4):629-34.
6. Madarasová Gecková A, Jarčuška P, Mareková M, Pella D, Siegfried L, Jarčuška P, et al.; HepaMeta Team. HepaMeta – Prevalence of hepatitis B/C and metabolic syndrome in population living in separated and segregated Roma settlements: a methodology for a cross-sectional population-based study using community-based approach. Cent Eur J Public Health. 2014 Mar;22 Suppl:S6-S11.
7. Singh RB, Fedacko J, Vargova V, Kumar A, Mohan V, Pella D, et al. Singh's verbal autopsy questionnaire for the assessment of causes of death, social autopsy, tobacco autopsy and dietary autopsy, based on medical records and interview. Acta Cardiol. 2011 Aug;66(4):471-81.
8. Singh RB, Ghosh S, Niaz MA, Rastogi V. Validation of physical activity and socioeconomic status questionnaire in relation to food intakes for the five city study and proposed classifications for lndians. J Assoc Physicians India. 1997;45:603-7.
9. Bogdanova K, Poczatkova H, Uherkova L, Riegrova D, Rypka M, Feher J, et al. Non-alcoholic fatty liver disease (NAFLD) - a novel common aspect of the metabolic syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):101-4.
10. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002 May;122(6):1649-57.
11. Kupčová V, Fedelešová M. Metabolic disorders, metabolic diseases and fatty liver. Trendy Hepatol. 2011;3(1):4-12. (In Slovak.)
12. Zima M. Nonalcoholic fatty liver disease - NAFLD-NASH. Trendy Hepatol. 2011;3(1):13-21. (In Slovak.)
13. McCullogh A. Natural history of nonalcoholic steatohepatitis. In: Arroyo V, Forns X, Garcia-Pagán J, Rodés J, editors. Progress in the treatment of liver diseases. Barcelona: Ars medica; 2003. p. 219-25.
14. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005 Jul;42(1):44-52.
15. Jarčuška P, Janičko M, Veselíny E, Jarčuška P, Skladaný L. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010 Aug 5;411(15-16):1009-17.
16. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009 Jan;13(1):9-19.
17. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004 Dec;40(6):1387-95.
18. Dukát A, Lietava J, Krahulec B, Čaprnda M, Vacula I, Sirotiaková J, et al.; IDEA Slovakia. The prevalence of abdominal obesity in Slovakia. The IDEA Slovakia study. Vnitr Lek. 2007 Apr;53(4):326-30. (In Slovak.)
19. Singh RB, Pella D, Mechirova V, Kartikey K, Demeester F, Tomar RS, et al. Prevalence of obesity, physical inactivity and undernutrition, a triple burden of diseases during transition in a developing economy. The Five City Study Group. Acta Cardiol. 2007 Apr;62(2):119-27.
20. Mendizabal I, Lao O, Marigorta UM, Wollstein A, Gusmão L, Ferak V, et al. Reconstructing the population history of European Romani from genome-wide data. Curr Biol. 2012 Dec 18;22(24):2342-9.
21. Koller T, Kollerová J, Hlavatý T, Huorka M, Payer J. Prevalence of liver disease markers among patients with metabolic risk factors. Vnitr Lek. 2010 Mar;56(3):183-9. (In Slovak)
22. Yamada Y, Ishizaki M, Kido T, Honda R, Tsuritani I, Nogawa K, et al. Relationship between serum gamma-glutamyl transpeptidase activity, blood pressure and alcohol consumption. J Hum Hypertens. 1989 Dec;3(6):409-17.
23. Yamada Y, Ishizaki M, Kido T, Honda R, Tsuritani I, Yamaya H. Relationship between serum gamma-glutamyl transpeptidase activity and blood pressure in middle-aged male and female non-drinkers. J Hum Hypertens. 1990 Dec;4(6):609-14.
24. López-Suárez A, Rodrígez Guerrero JM, Elvira-González J, Beltrán-Robles M, Cañas-Hormigo F, Bascuñana-Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol. 2011 Nov;23(11):1011-7.
25. Nilssen O, Førde OH, Brenn T. The Tromsø Study. Distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol. 1990 Aug;132(2):318-26.
26. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S186-S190.
27. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8 Suppl 1:S4-S8.
28. Zhang H, Li Q, Sun J, Wang C, Gu Q, Feng X, et al. Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China. Int J Med Sci. 2011;8(4):321-31.
29. Manco M, Bedogni G, Marcellini M, Devito R, Ciampalini P, Sartorelli MR, et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut. 2008 Sep;57(9):1283-7.
30. Umeki S, Hisamoto N, Hara Y. Study on background factors associated with impaired glucose tolerance and/or diabetes mellitus. Acta Endocrinol (Copenh). 1989 Jun;120(6):729-34.
31. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007 Apr;45(4):846-54.
32. Janzon L, Franzén J, Lindell SE, Trell E. Blood lipid variability in relation to relative weight and biochemical markers of tobacco and alcohol consumption. Postgrad Med J. 1985 Jun;61(716):505-8.
33. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1224-9, 1229.e1-2.
34. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007 Jul;47(1):135-41.
35. Abel T, Feher J, Dinya E, Eldin M, Kovacs A. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit. 2009 Dec;15(12):6-11.
36. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006 May;22(5):873-83.
37. Bugianesi E, Gastaldelli A. Hepatic and cardiac steatosis: are they coupled? Heart Fail Clin. 2012 Oct;8(4):663-70.
38. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004 Apr 1;350(14):1387-97.
39. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511.
40. Kuppan G, Anjana RM, Deepa M, Paramasivam P, Chandrakumar S, Kaliyaperumal V, et al. Inflammatory markers in relation to nonalcoholic fatty liver disease in urban South Indians. Diabetes Technol Ther. 2012 Feb;14(2):152-8.
41. Babinska I, Dankulincova Veselska Z, Bobakova D, Pella D, Panico S, Reijneveld SA, et al.; HEPA-META team. Is the cardiovascular risk profile of people living in Roma settlements worse in comparison with the majority population in Slovakia? Int J Public Health. 2013 Jun;58(3):417-25.
42. Sudzinova A, Nagyova I, Studencan M, Rosenberger J, Skodova Z, Vargova H, et al. Roma coronary heart disease patients have more medical risk factors and greater severity of coronary heart disease than non-Roma. Int J Public Health. 2013 Jun;58(3):409-15.
43. Pella D, Otsuka K, Singh RB. Metabolic syndrome: a disease of the brain. Open Nutraceuticals Journal. 2011;4:107-18.
44. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al.; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012 Jan;55(1):77-85.
45. Ahluwalia N, Genoux A, Ferrieres J, Perret B, Carayol M, Drouet L, et al. Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr. 2010 Apr;140(4):812-6.
46. Pella D, Singh RB, Otsuka K, Chiang C, Joshi SR. Nutritional predictors and modulators of insulin resistance. Journal of Nutritional & Environmental Medicine. 2004;14(1):3-16.
47. Wannamethee SG, Lennon L, Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis. 2008 Nov;201(1):168-75.
48. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2729-35.
49. Stojakovic T, Scharnagl H, Trauner M, Pieske B, Wellnitz B, Seelhorst U, et al. Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography - The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis. 2010 Feb;208(2):564-71.
50. Sattar N. Steatosis and cardiovascular events: a truly independent casual link? In: Gines P, Forns X, Abraldes J, Fernández J, Bataller R, Rodés J, et al., editors. Therapy in liver diseases. Barcelona: Elsevier Doyma; 2011. p. 135-41.